Zobrazeno 1 - 10
of 747
pro vyhledávání: '"Makoto, Nishio"'
Autor:
Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-16 (2024)
Abstract Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma
Externí odkaz:
https://doaj.org/article/2452462725da441b9de6e8ec14089d0a
Autor:
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 10, Pp 788-796 (2024)
Abstract Background It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genet
Externí odkaz:
https://doaj.org/article/93acc07c0f8341ceb4a0c0b39dc0fe16
Autor:
Shigehiro Yagishita, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Satoru Miura, MD, PhD, Koji Tamada, MD, PhD, Hiroshi Kagamu, MD, PhD, Akinobu Hamada, PhD, Mayu Ohuchi, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Satoshi Hara, MD, Takashi Kijima, MD, PhD, Fujita Masaki, MD, PhD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Masahiro Tatsuno, MSc, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100683- (2024)
Introduction: This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC and explored the relationship between PK parameters, effectiveness, and adverse
Externí odkaz:
https://doaj.org/article/5313a5b432ab4c3892187d0d69ddf659
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Hironori Ninomiya, Yukiko Sato, Kentaro Inamura, Akito Dobashi, Kengo Takeuchi, Hiroki Mitani, Mingyon Mun, Makoto Nishio, Yuichi Ishikawa
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Introduction NUT carcinoma is a rare cancer associated with a poor prognosis. Because of its rarity, its diagnosis is challenging and is usually made by excluding other diagnoses. Immunohistochemical analysis is a reliable technique that con
Externí odkaz:
https://doaj.org/article/7d6547d3cafb4ea18f0277d57cb2f443
Autor:
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding
Externí odkaz:
https://doaj.org/article/b24524fa05214c18b25d982517bfb2eb
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 402-409 (2024)
Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertin
Externí odkaz:
https://doaj.org/article/bf9f4e65fe294138b6c32c0d9d62d1af
Autor:
Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100632- (2024)
Introduction: Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unpla
Externí odkaz:
https://doaj.org/article/2624fb2887e641e3b17201306189bdef
Autor:
Yoshiaki Amino, Siew‐Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3317-3322 (2023)
Abstract Background KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all reports are based on analysis of tissue samples. Rec
Externí odkaz:
https://doaj.org/article/65050a39348140f4a87a937f35d99782
Autor:
Hye Ryun Kim, Shunichi Sugawara, Jong‐Seok Lee, Jin‐Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17061-17067 (2023)
Abstract Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐lin
Externí odkaz:
https://doaj.org/article/b0fcd685eeec41798eee2fd83380a4ba